AVITA Medical (ASX:AVH), a regenerative medicine company with a technology platform designed to address unmet medical needs in therapeutic skin restoration, will announce new preliminary data relating to its RECELL Autologous Cell Harvesting Device.
The company said three posters at the World Congress of Dermatology in Italy will highlight the potential use of the RECELL system for the treatment of vitiligo and facial acne scars.
“Building on the foundation of long-term safety and efficacy of the RECELL® System for the treatment of burn patients, we look forward to presenting data at the World Congress of Dermatology exploring the use of this innovative therapy for regenerative dermatology,” said Dr Michael Perry, AVITA Medical’s CEO.
“We are committed to pursuing the full potential of the RECELL® System as a meaningful treatment option to advance patient care in areas with significant unmet medical need.”
The RECELL System uses a small amount of a patient’s own skin to prepare Spray-On Skin Cells at the point of care. It is approved by the US FDA for the treatment of acute thermal burns in patients 18 years and older. In other international markets, it is approved to promote skin healing in a wide range of applications including burns, acute wounds, scars and vitiligo.